Alto Neuroscience (NYSE:ANRO) Stock Rating Reaffirmed by William Blair

William Blair reaffirmed their outperform rating on shares of Alto Neuroscience (NYSE:ANRO) in a research report report published on Wednesday, RTT News reports.

ANRO has been the topic of a number of other reports. TD Cowen began coverage on Alto Neuroscience in a research report on Tuesday, February 27th. They set an outperform rating on the stock. Jefferies Financial Group began coverage on Alto Neuroscience in a research note on Tuesday, February 27th. They issued a buy rating and a $33.00 target price for the company. Stifel Nicolaus reissued a buy rating and issued a $32.00 target price on shares of Alto Neuroscience in a research note on Monday, March 25th. Finally, Robert W. Baird began coverage on Alto Neuroscience in a research note on Tuesday, February 27th. They issued an outperform rating and a $32.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Alto Neuroscience presently has a consensus rating of Buy and an average price target of $32.33.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $12.03 on Wednesday. Alto Neuroscience has a one year low of $10.85 and a one year high of $24.00. The stock’s 50 day simple moving average is $13.31. The company has a debt-to-equity ratio of 0.05, a quick ratio of 26.02 and a current ratio of 26.02.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.30). As a group, equities research analysts forecast that Alto Neuroscience will post -2.93 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Nicholas Conrad Smith acquired 6,150 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The stock was acquired at an average cost of $16.36 per share, with a total value of $100,614.00. Following the completion of the purchase, the chief financial officer now directly owns 26,866 shares in the company, valued at $439,527.76. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently made changes to their positions in ANRO. University of Texas Texas AM Investment Managment Co. bought a new position in Alto Neuroscience during the first quarter worth about $340,000. Zimmer Partners LP bought a new stake in Alto Neuroscience during the first quarter worth about $1,151,000. AWM Investment Company Inc. bought a new stake in Alto Neuroscience during the first quarter worth about $4,592,000. Artal Group S.A. bought a new stake in Alto Neuroscience during the first quarter worth about $5,372,000. Finally, Jennison Associates LLC bought a new stake in Alto Neuroscience during the first quarter worth about $7,039,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.